Fields marked with an * are required

Contact a site to learn more about the HER2CLIMB Study

Your chosen site:

Fields marked with an * are required

To be eligible for the HER2CLIMB study you must have a diagnosis of locally advanced or metastatic HER2+ breast cancer and have received the following common therapies for the treatment of breast cancer:

  • trastuzumab (Herceptin®)
  • pertuzumab (Perjeta®)
  • T-DMI (Kadcyla®)

Have you received any of the following treatments?

Where allowed, you will be contacted by a local study representative who will tell you more about the study. They will help determine whether you may be eligible to participate.

Share information about the HER2CLIMB study with others

To share this study information with others via email, click here

FacebookTwitterGoogle+